964 related articles for article (PubMed ID: 31156534)
1. Quantitative
Zhao Q; Liu M; Ha L; Zhou Y;
Front Neurol; 2019; 10():486. PubMed ID: 31156534
[TBL] [Abstract][Full Text] [Related]
2. Sex modulates the ApoE ε4 effect on brain tau deposition measured by
Liu M; Paranjpe MD; Zhou X; Duy PQ; Goyal MS; Benzinger TLS; Lu J; Wang R; Zhou Y
Theranostics; 2019; 9(17):4959-4970. PubMed ID: 31410194
[TBL] [Abstract][Full Text] [Related]
3. Association of sex and APOE ε4 with brain tau deposition and atrophy in older adults with Alzheimer's disease.
Yan S; Zheng C; Paranjpe MD; Li J; Benzinger TLS; Lu J; Zhou Y
Theranostics; 2020; 10(23):10563-10572. PubMed ID: 32929366
[TBL] [Abstract][Full Text] [Related]
4. Association between long-term donepezil treatment and brain regional amyloid and tau burden among individuals with mild cognitive impairment assessed using
Li J; Zheng C; Ge Q; Yan S; Paranjpe MD; Hu S; Zhou Y;
J Neurosci Res; 2022 Feb; 100(2):670-680. PubMed ID: 34882830
[TBL] [Abstract][Full Text] [Related]
5. The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study.
Paranjpe MD; Chen X; Liu M; Paranjpe I; Leal JP; Wang R; Pomper MG; Wong DF; Benzinger TLS; Zhou Y;
Neuroimage Clin; 2019; 22():101795. PubMed ID: 30991617
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tau deposition using
Bullich S; Mueller A; De Santi S; Koglin N; Krause S; Kaplow J; Kanekiyo M; Roé-Vellvé N; Perrotin A; Jovalekic A; Scott D; Gee M; Stephens A; Irizarry M
Alzheimers Res Ther; 2022 Jul; 14(1):105. PubMed ID: 35897078
[TBL] [Abstract][Full Text] [Related]
7. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals.
Yan S; Zheng C; Paranjpe MD; Li Y; Li W; Wang X; Benzinger TLS; Lu J; Zhou Y
Brain; 2021 Nov; 144(10):3201-3211. PubMed ID: 33876815
[TBL] [Abstract][Full Text] [Related]
8. Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer's Disease.
Qiao Z; Wang G; Zhao X; Wang K; Fan D; Chen Q; Ai L
Front Aging Neurosci; 2022; 14():841942. PubMed ID: 35663582
[TBL] [Abstract][Full Text] [Related]
9. Lack of association between bridging integrator 1 (
Schaeverbeke J; Luckett ES; Gabel S; Reinartz M; De Meyer S; Cleynen I; Sleegers K; Van Broeckhoven C; Bormans G; Serdons K; Van Laere K; Dupont P; Vandenberghe R;
Alzheimers Dement (N Y); 2022; 8(1):e12227. PubMed ID: 35229019
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
11. Regional [
Wolters EE; Ossenkoppele R; Verfaillie SCJ; Coomans EM; Timmers T; Visser D; Tuncel H; Golla SSV; Windhorst AD; Boellaard R; van der Flier WM; Teunissen CE; Scheltens P; van Berckel BNM
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2866-2878. PubMed ID: 32291510
[TBL] [Abstract][Full Text] [Related]
12. Partial volume correction in longitudinal tau PET studies: is it really needed?
Costoya-Sánchez A; Moscoso A; Sobrino T; Ruibal Á; Grothe MJ; Schöll M; Silva-Rodríguez J; Aguiar P;
Neuroimage; 2024 Apr; 289():120537. PubMed ID: 38367651
[TBL] [Abstract][Full Text] [Related]
13. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
14.
Xu X; Ruan W; Liu F; Gai Y; Liu Q; Su Y; Liang Z; Sun X; Lan X
Front Aging Neurosci; 2021; 13():789054. PubMed ID: 35221982
[TBL] [Abstract][Full Text] [Related]
15. Tau PET With
Huang CC; Hsiao IT; Huang CY; Weng YC; Huang KL; Liu CH; Chang TY; Wu HC; Yen TC; Lin KJ
Front Neurol; 2019; 10():503. PubMed ID: 31191427
[No Abstract] [Full Text] [Related]
16. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
[TBL] [Abstract][Full Text] [Related]
18. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
19. Associations between [
La Joie R; Bejanin A; Fagan AM; Ayakta N; Baker SL; Bourakova V; Boxer AL; Cha J; Karydas A; Jerome G; Maass A; Mensing A; Miller ZA; O'Neil JP; Pham J; Rosen HJ; Tsai R; Visani AV; Miller BL; Jagust WJ; Rabinovici GD
Neurology; 2018 Jan; 90(4):e282-e290. PubMed ID: 29282337
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Binette AP; Vogel JW; Klein G; Borroni E; Tonietto M; Strandberg O; Mattsson-Carlgren N; Palmqvist S; Pontecorvo MJ; Iaccarino L; Stomrud E; Ossenkoppele R; Smith R; Hansson O;
JAMA Neurol; 2023 Jun; 80(6):614-623. PubMed ID: 37155176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
